Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 2;6:e2100267. doi: 10.1200/PO.21.00267

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 4. — (A) The landscape of co-occurring mutations in all patients with evaluable POLE mutations (n = 450). The most common co-occurring mutations included TP53 (52%), ARID1A (22%), BRCA2 (21%), KRAS (21%), NF1 (19%), NOTCH3 (18%), NOTCH1 (18%), ATM (18%), PIK3CA (17%), SETD2 (17%), and SMARCA4 (17%). Mutations are classified as pathogenic (green), benign (blue), and VUS (orange). Patients with pathogenic POLE mutations had more comutations in DDR genes as shown in the (B) heat map and (C) bar graphs above. DDR, DNA damage response; VUS, variant of unknown significance.